

Drugging the Cancers Addicted to DNA Repair

Journal of the National Cancer Institute
109,

DOI: [10.1093/jnci/djx059](https://doi.org/10.1093/jnci/djx059)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The evolving role of DNA inter-strand crosslinks in chemotherapy. <i>Current Opinion in Pharmacology</i> , 2018, 41, 20-26.	1.7	41
2	The Radiobiology of Proton Therapy: Challenges and Opportunities Around Relative Biological Effectiveness. <i>Clinical Oncology</i> , 2018, 30, 285-292.	0.6	56
3	A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 2044-2049.	3.2	56
4	Targeting DNA repair: the genome as a potential biomarker. <i>Journal of Pathology</i> , 2018, 244, 586-597.	2.1	41
5	Advances in therapeutic targeting of the DNA damage response in cancer. <i>DNA Repair</i> , 2018, 66-67, 24-29.	1.3	46
6	A lncRNA GUARDINg genome integrity. <i>Nature Cell Biology</i> , 2018, 20, 371-372.	4.6	2
7	ADP-Ribosylation, a Multifaceted Posttranslational Modification Involved in the Control of Cell Physiology in Health and Disease. <i>Chemical Reviews</i> , 2018, 118, 1092-1136.	23.0	186
8	Carcinogenesis: Role of Reactive Oxygen and Nitrogen Species. , 2018, , 296-296.		0
9	Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors. <i>Cancers</i> , 2018, 10, 487.	1.7	154
10	Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers. <i>Clinical Cancer Research</i> , 2018, 24, 4887-4899.	3.2	74
11	T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system. <i>Scientific Reports</i> , 2018, 8, 9966.	1.6	17
12	Nucleotide Excision Repair Factor XPC Ameliorates Prognosis by Increasing the Susceptibility of Human Colorectal Cancer to Chemotherapy and Ionizing Radiation. <i>Frontiers in Oncology</i> , 2018, 8, 290.	1.3	18
13	The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells. <i>Cancer Biology and Therapy</i> , 2018, 19, 786-796.	1.5	23
14	Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. <i>Cell Reports</i> , 2018, 23, 3127-3136.	2.9	68
15	Integrative genomic analysis identifies associations of molecular alterations to APOBEC and BRCA1/2 mutational signatures in breast cancer. <i>Molecular Genetics & Genomic Medicine</i> , 2019, 7, e810.	0.6	7
16	Autophagy suppression enhances DNA damage and cell death upon treatment with PARP inhibitor Niraparib in laryngeal squamous cell carcinoma. <i>Applied Microbiology and Biotechnology</i> , 2019, 103, 9557-9568.	1.7	8
17	Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes. <i>Cancers</i> , 2019, 11, 1373.	1.7	13
18	Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 589-601.	1.1	8

#	ARTICLE	IF	CITATIONS
19	Inhibition of Wee1 sensitizes AML cells to ATR inhibitor VE-822-induced DNA damage and apoptosis. <i>Biochemical Pharmacology</i> , 2019, 164, 273-282.	2.0	29
20	Identification of Novel Interaction Partners of Ets-1: Focus on DNA Repair. <i>Genes</i> , 2019, 10, 206.	1.0	1
21	DNA Repair Gene Expression Adjusted by the PCNA Metagene Predicts Survival in Multiple Cancers. <i>Cancers</i> , 2019, 11, 501.	1.7	4
22	Small Molecule Docking of DNA Repair Proteins Associated with Cancer Survival Following PCNA Metagene Adjustment: A Potential Novel Class of Repair Inhibitors. <i>Molecules</i> , 2019, 24, 645.	1.7	7
23	Development and implementation of precision therapies targeting base-excision DNA repair in BRCA1-associated tumors. <i>Expert Review of Precision Medicine and Drug Development</i> , 2019, 4, 11-25.	0.4	1
24	DNA damage repair alterations modulate M2 polarization of microglia to remodel the tumor microenvironment via the p53-mediated MDK expression in glioma. <i>EBioMedicine</i> , 2019, 41, 185-199.	2.7	77
25	Targeting DNA Double-Strand Break Repair Pathways to Improve Radiotherapy Response. <i>Genes</i> , 2019, 10, 25.	1.0	111
26	Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 1098-1101.	0.6	12
27	Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts. <i>European Urology</i> , 2020, 77, 144-155.	0.9	46
28	Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma. <i>Leukemia</i> , 2020, 34, 234-244.	3.3	80
29	Epigenetic based synthetic lethal strategies in human cancers. <i>Biomarker Research</i> , 2020, 8, 44.	2.8	19
30	Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification. <i>Drug Resistance Updates</i> , 2020, 53, 100720.	6.5	107
31	ATM inhibition synergizes with fenofibrate in high grade serous ovarian cancer cells. <i>Heliyon</i> , 2020, 6, e05097.	1.4	4
32	The SWI/SNF ATPase BRG1 stimulates DNA end resection and homologous recombination by reducing nucleosome density at DNA double strand breaks and by promoting the recruitment of the CtIP nuclease. <i>Cell Cycle</i> , 2020, 19, 3096-3114.	1.3	18
33	UBC13-Mediated Ubiquitin Signaling Promotes Removal of Blocking Adducts from DNA Double-Strand Breaks. <i>IScience</i> , 2020, 23, 101027.	1.9	17
34	Distinct roles of structure-specific endonucleases EEPD1 and Metnase in replication stress responses. <i>NAR Cancer</i> , 2020, 2, zcaa008.	1.6	11
35	DNA Damage: From Threat to Treatment. <i>Cells</i> , 2020, 9, 1665.	1.8	99
36	Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End Joining. <i>Cell Reports</i> , 2020, 32, 108068.	2.9	29

#	ARTICLE	IF	CITATIONS
37	DNA Repair Syndromes and Cancer: Insights Into Genetics and Phenotype Patterns. <i>Frontiers in Pediatrics</i> , 2020, 8, 570084.	0.9	42
38	DNA Damage-Inducing Anticancer Therapies: From Global to Precision Damage. <i>Cancers</i> , 2020, 12, 2098.	1.7	57
39	Exploiting DNA repair defects in triple negative breast cancer to improve cell killing. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095835.	1.4	27
40	Development and validation of a DNA repair gene signature for prognosis prediction in Colon Cancer. <i>Journal of Cancer</i> , 2020, 11, 5918-5928.	1.2	9
41	Inhibition of DNA Repair in Cancer Therapy: Toward a Multi-Target Approach. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6684.	1.8	24
42	DNA Repair Biosensor-Identified DNA Damage Activities of Endophyte Extracts from <i>Garcinia cowa</i> . <i>Biomolecules</i> , 2020, 10, 1680.	1.8	0
43	Targeting DNA Damage Response in Prostate and Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8273.	1.8	50
44	Novel allosteric PARP1 inhibitors for the treatment of BRCA-deficient leukemia. <i>Medicinal Chemistry Research</i> , 2020, 29, 962-978.	1.1	4
45	Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers. <i>Frontiers in Oncology</i> , 2020, 10, 670.	1.3	13
46	Digoxin Enhances the Anticancer Effect on Non-Small Cell Lung Cancer While Reducing the Cardiotoxicity of Adriamycin. <i>Frontiers in Pharmacology</i> , 2020, 11, 186.	1.6	37
47	Synergistic lethality between PARP-trapping and alantolactone-induced oxidative DNA damage in homologous recombination-proficient cancer cells. <i>Oncogene</i> , 2020, 39, 2905-2920.	2.6	37
48	Role of Rad51 and DNA repair in cancer: A molecular perspective. , 2020, 208, 107492.		64
49	Clustered DNA Double-Strand Breaks: Biological Effects and Relevance to Cancer Radiotherapy. <i>Genes</i> , 2020, 11, 99.	1.0	118
50	The high protein expression of FOXO3, but not that of FOXO1, is associated with markers of good prognosis. <i>Scientific Reports</i> , 2020, 10, 6920.	1.6	5
51	Dietary riboflavin deficiency induces ariboflavinosis and esophageal epithelial atrophy in association with modification of gut microbiota in rats. <i>European Journal of Nutrition</i> , 2021, 60, 807-820.	1.8	19
52	Reserpine inhibits DNA repair, cell proliferation, invasion and induces apoptosis in oral carcinogenesis via modulation of TGF- β 2 signaling. <i>Life Sciences</i> , 2021, 264, 118730.	2.0	11
53	Human CtIP: A "double agent"™ in DNA repair and tumorigenesis. <i>Seminars in Cell and Developmental Biology</i> , 2021, 113, 47-56.	2.3	25
54	The role of DNA damage and repair in liver cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188493.	3.3	23

#	ARTICLE	IF	CITATIONS
55	The rediscovery of platinum-based cancer therapy. <i>Nature Reviews Cancer</i> , 2021, 21, 37-50.	12.8	452
56	Exploiting DNA repair pathways for tumor sensitization, mitigation of resistance, and normal tissue protection in radiotherapy. , 2021, 4, 244-263.		14
58	Targeting protein-protein interactions in the DNA damage response pathways for cancer chemotherapy. <i>RSC Chemical Biology</i> , 2021, 2, 1167-1195.	2.0	14
59	Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy. <i>ESMO Open</i> , 2021, 6, 100034.	2.0	0
60	The Role of Nucleotide Excision Repair in Cisplatin-Induced Peripheral Neuropathy: Mechanism, Prevention, and Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1975.	1.8	10
61	EPHA2 Interacts with DNA-PKcs in Cell Nucleus and Controls Ionizing Radiation Responses in Non-Small Cell Lung Cancer Cells. <i>Cancers</i> , 2021, 13, 1010.	1.7	8
62	RRM2B Is Frequently Amplified Across Multiple Tumor Types: Implications for DNA Repair, Cellular Survival, and Cancer Therapy. <i>Frontiers in Genetics</i> , 2021, 12, 628758.	1.1	9
63	Early Steps of Hepatitis B Life Cycle: From Capsid Nuclear Import to cccDNA Formation. <i>Viruses</i> , 2021, 13, 757.	1.5	16
64	PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation. <i>Genes</i> , 2021, 12, 849.	1.0	10
65	The Effects of Localized Heat on the Hallmarks of Cancer. <i>Advanced Therapeutics</i> , 2021, 4, 2000267.	1.6	19
66	Selective Inhibition of DNA Polymerase β by a Covalent Inhibitor. <i>Journal of the American Chemical Society</i> , 2021, 143, 8099-8107.	6.6	8
67	Validating TDP1 as an Inhibition Target for the Development of Chemosensitizers for Camptothecin-Based Chemotherapy Drugs. <i>Oncology and Therapy</i> , 2021, 9, 541-556.	1.0	11
68	Analyzing the Opportunities to Target DNA Double-Strand Breaks Repair and Replicative Stress Responses to Improve Therapeutic Index of Colorectal Cancer. <i>Cancers</i> , 2021, 13, 3130.	1.7	13
69	Activation of the DDR Pathway Leads to the Down-Regulation of the TGF β Pathway and a Better Response to ICIs in Patients With Metastatic Urothelial Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 634741.	2.2	20
70	Suppression of DNA Polymerase β Activity Is Synthetically Lethal in BRCA1-Deficient Cells. <i>ACS Chemical Biology</i> , 2021, 16, 1339-1343.	1.6	2
71	The Prognostic Value of the DNA Repair Gene Signature in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 710694.	1.3	2
72	Roles of homologous recombination in response to ionizing radiation-induced DNA damage. <i>International Journal of Radiation Biology</i> , 2023, 99, 903-914.	1.0	9
73	Protein Domain Specific Covalent Inhibition of Human DNA Polymerase β . <i>ChemBioChem</i> , 2021, 22, 2619-2623.	1.3	1

#	ARTICLE	IF	CITATIONS
74	Screening of DNA Damage Repair Genes Involved in the Prognosis of Triple-Negative Breast Cancer Patients Based on Bioinformatics. <i>Frontiers in Genetics</i> , 2021, 12, 721873.	1.1	4
75	Targeted Therapy as a Potential De-Escalation Strategy in Locally Advanced HPV-Associated Oropharyngeal Cancer: A Literature Review. <i>Frontiers in Oncology</i> , 2021, 11, 730412.	1.3	6
76	Cinobufagin-induced DNA damage response activates G2/M checkpoint and apoptosis to cause selective cytotoxicity in cancer cells. <i>Cancer Cell International</i> , 2021, 21, 446.	1.8	8
77	The Safe Path at the Fork: Ensuring Replication-Associated DNA Double-Strand Breaks are Repaired by Homologous Recombination. <i>Frontiers in Genetics</i> , 2021, 12, 748033.	1.1	21
78	Cell cycle control and DNA-damage signaling in mammals. , 2021, , 237-255.		0
79	SLX4 mediates DNA damage responses to replication stress induced by DNA-protein interactions. <i>Journal of Cell Biology</i> , 2021, 220, .	2.3	12
80	PAM-OBG: A monoamine oxidase B specific prodrug that inhibits MGMT and generates DNA interstrand crosslinks, potentiating temozolomide and chemoradiation therapy in intracranial glioblastoma. <i>Oncotarget</i> , 2018, 9, 23923-23943.	0.8	9
81	DNA Double Strand Break Repair - Related Synthetic Lethality. <i>Current Medicinal Chemistry</i> , 2019, 26, 1446-1482.	1.2	9
82	Recent Advances in Use of Topoisomerase Inhibitors in Combination Cancer Therapy. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 730-740.	1.0	24
83	Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells. <i>ELife</i> , 2019, 8, .	2.8	80
84	A signature of tumor DNA repair genes associated with the prognosis of surgically-resected lung adenocarcinoma. <i>PeerJ</i> , 2020, 8, e10418.	0.9	6
85	Treatment of Triple Negative Cell Lines with Olaparib to Block DNA Repair. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 2036-2045.	0.9	1
86	The fellowship of the RING: BRCA1, its partner BARD1 and their liaison in DNA repair and cancer. , 2022, 232, 108009.		3
87	De moleculaire biologie van urologische tumoren. , 2018, , 197-208.		0
92	Pan-cancer analysis of non-oncogene addiction to DNA repair. <i>Scientific Reports</i> , 2021, 11, 23264.	1.6	5
93	Nucleases and Co-Factors in DNA Replication Stress Responses. <i>Dna</i> , 2022, 2, 68-85.	0.4	4
94	A Novel DNA Damage Repair-Related Gene Signature for Predicting Glioma Prognosis. <i>International Journal of General Medicine</i> , 2021, Volume 14, 10083-10101.	0.8	3
96	A Preclinical Study to Repurpose Spironolactone for Enhancing Chemotherapy Response in Bladder Cancer. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 786-798.	1.9	3

#	ARTICLE	IF	CITATIONS
97	Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system. <i>International Journal of Hematology</i> , 2022, , .	0.7	0
98	Targeting mitochondrial DNA polymerase gamma for selective inhibition of MLH1 deficient colon cancer growth. <i>PLoS ONE</i> , 2022, 17, e0268391.	1.1	3
99	Chronically Radiation-Exposed Survivor Glioblastoma Cells Display Poor Response to Chk1 Inhibition under Hypoxia. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7051.	1.8	3
100	Targeting Replication Stress Response Pathways to Enhance Genotoxic Chemo- and Radiotherapy. <i>Molecules</i> , 2022, 27, 4736.	1.7	10
101	Combined PARP and Dual Topoisomerase Inhibition Potentiates Genome Instability and Cell Death in Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10503.	1.8	4
102	BMN673 Is a PARP Inhibitor with Unique Radiosensitizing Properties: Mechanisms and Potential in Radiation Therapy. <i>Cancers</i> , 2022, 14, 5619.	1.7	3
103	A rapid multiplex cell-free assay on biochip to evaluate functional aspects of double-strand break repair. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
104	Defektif Homolog Rekombinasyon DNA Tamiri ve PARP İnhibisyonu Arasındaki Sentetik Letal Etkileşim. <i>Journal of the Institute of Science and Technology</i> , 0, , 2459-2475.	0.3	0
105	The role of SWI/SNF chromatin remodelers in the repair of DNA double strand breaks and cancer therapy. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	0
106	Construction of a DNA damage repair gene signature for predicting prognosis and immune response in breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
107	Nanomedicines with high drug availability and drug sensitivity overcome hypoxia-associated drug resistance. <i>Biomaterials</i> , 2023, 294, 122023.	5.7	10